Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion

International Journal of Pharmaceutics

Volumn 199, Issue 1, 2000, Pages 17-28

  Lyons, Kym C ^a   Charman, William N ^a   Miller, Robert ^b,c   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b TEVA PHARMACEUTICALS   (Israel)

^c Aoris Nova   (Australia)

Author keywords

Absorption; GMDP; Intestinal instability; Intestinal permeability; Microemulsion; Peptide

Indexed keywords

CAPTEX 355; CARBON 14; DIAZEPAM; MANNITOL; N ACETYLGLUCOSAMINYL N ACETYLMURAMYL DIPEPTIDE; N ACETYLNEURAMINIC ACID DERIVATIVE; OCTANOIN; POLYSORBATE 80; TRIACYLGLYCEROL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG FECES LEVEL; DRUG STABILITY; DRUG TRANSPORT; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; ISOTOPE LABELING; LARGE INTESTINE; LIQUID SCINTILLATION COUNTING; MALE; MICROEMULSION; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; RABBIT; RAT; SMALL INTESTINE; STOMACH;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DUODENUM; EMULSIONS; FECES; HALF-LIFE; ILEUM; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTUBATION, GASTROINTESTINAL; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SOLUTIONS;

EID: 0034630042     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00349-5     Document Type: Article

References (21)

1. Burton P.S., Conradi R.A., Ho N.F., Hilgers A.R., Borchardt R.T. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85:1996;1336-1340.
2. Constantinides P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12:1995;1561-1572.
3. Constantinides P.P., Scalart J.P., Lancaster C. et al. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 11:1994;1385-1390.
4. Constantinides P.P., Welzel G., Ellens H. et al. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 13:1996;210-215.
5. Dinarello C.A., Elin R.J., Chedid L., Wolff S.M. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J. Infect. Dis. 138:1978;760-767.
6. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59:1974;1317-1325.
7. Heizmann J., Langguth P., Biber A. et al. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brushborder enzymes. Peptides. 17:1996;1083-1089.
8. Knipp G.T., Vander Velde D.G., Siahaan T.J., Borchardt R.T. The effect of beta-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharm. Res. 14:1997;1332-1340.
9. Krondahl E., Orzechowski A., Ekstrom G., Lennernas H. Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharm. Res. 14:1997;1780-1785.
10. Langguth P., Bohner V., Heizmann J. et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Rel. 46:1997;7.
11. Leclerc C., Juy D., Bourgeois E., Chedid L. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell. Immunol. 45:1979;199-206.
12. Lindmark T., Schipper N., Lazorova L., de Boer A.G., Artursson P. Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes. J. Drug Target. 5:1998;215-223.
13. Lundin P.D., Bojrup M., Ljusberg-Wahren H., Westrom B.R., Lundin S. Enhancing effects of monohexanoin and two other medium-chain glyceride vehicles on intestinal absorption of desmopressin (dDAVP). J. Pharmcol. Exp. Ther. 282:1997;585-590.
14. Lundin P.D.P., Lundin S., Olsson H. et al. Enhanced intestinal absorption of oxytocin peptide analogues in the absence of pancreatic juice in pigs. Pharm. Res. 12:1995;1478-1482.
15. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharrn. Res. 13:1996;528-534.
16. Rao R.K., Baker R.D., Baker S.S. Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides. 19:1998;495-504.
17. Sarclaux J.M., Acar L., Sado P.A. Using microemulsion formulations for oral delivery of therapeutic peptides. Int. J. Pharm. 120:1995;127-136.
18. Smith P.L. Methods for evaluating intestinal permeability and metabolism in vitro. Pharm. Biotech. 8:1996;13-34.
19. Tsubura E., Azuma I., Une T. Muroctasin, a muramyl dipeptide derivative, Arzneim. Forsch Drug Res. 38:1988;951-952.
20. Utsugi T., Schroit A.J., Connor J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51:1991;3062-3066.
21. Yamamoto A., Okagawa T., Kotani A. et al. Effects of different absorption enhancers on the permeation of ebiratide, an ACTH analogue, across intestinal membranes. J. Pharm. Pharmacol. 49:1997;1057-1061.